Pacira Pharmaceuticals, Inc.'s
) pain management drug Exparel is currently approved by the U.S.
Food and Drug Administration (FDA) for administration into the
surgical site to produce postsurgical analgesia. The drug was
approved by the FDA in the final quarter of 2011 and launched in
Apr 2012. A dedicated sales force commercializes Exparel, driving
Exparel has generated $25.1 million in the first year of
launch. In the second quarter of 2013, net Exparel revenues were
$15.2 million, up sequentially by 46.2%. Pacira has joined forces
with CrossLink Bioscience for the promotion of Exparel for
postsurgical pain management.
Under the five-year agreement, CrossLink will act as a local
agent and a lead partner in the collaboration with additional
distributors in selected markets across the U.S. to promote and
sell Exparel. CrossLink will be paid on the basis of performance
in designated hospitals.
A pilot program involving distributors from several orthopedic
companies with exclusive territory designations was held in Apr
2013. This collaboration is an extension of that pilot
Currently, Exparel is in two phase III nerve block studies -
one where it is studied as a femoral nerve block for patients
undergoing total knee arthroplasty while the other study
evaluates the safety and efficacy of Exparel in intercostal nerve
block for posterolateral thoracotomy. In Aug 2013, Pacira
announced a new study for the use of Exparel infiltrated into the
transversus abdominis plane for postsurgical analgesia in
abdominal hernia repair.
Pacira currently carries a Zacks Rank #3 (Hold). Currently,
Jazz Pharmaceuticals Ltd.
) and Actelion Ltd. (
) look more attractive with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
PACIRA PHARMACT (PCRX): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.